Moreover, Iwama E et al. reported that the detection of EGFR mutation after 4 and 24 weeks of EGFR TKI therapy was 13.3% and 0%, respectively, from 19 patients with mutant NSCLC [40]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.